ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4978ometendo-4978Research ArticleСтатьиArticlesИзбыточный вес и ожирение - проблема медицинская, а не косметическаяIzbytochnyy ves i ozhirenie - problema meditsinskaya, a ne kosmeticheskayaIvlevaA Yabourk@yandex.ruBurkovS G-20101509201073№3 (2010)1519Copyright © Ivleva A.Y., Burkov S.G., 20102010Ivleva A.Y., Burkov S.G.Ivleva A.Y., Burkov S.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4978

В статье рассматриваются вопросы эпидемиологии, классификации ожирения, риски развития различной соматической патологии при избыточном весе и ожирении. Приводятся результаты клинических исследований по применению орлистата в терапии пациентов, страдающих ожирением.

The article covers the issues of epidemiology, considering the classification of obesity, the risks of development of various somatic diseases related to overweight and obesity. The results of clinical studies of orlistat use in the treatment of obese patients are reported.

ожирениеизбыточный весиндекс массы телаорли- статОрсотенobesityoverweightbody mass indexorlistatOrsotenReferencesБессен Д.Г., Кушнер Р. Избыточный вес и ожирение. Профилактика, диагностика и лечение. - М.: ЗАО «Изд. БИНОМ», 2004. - 240 с.Бессен Д.Г., Кушнер Р. Избыточный вес и ожирение. Профилактика, диагностика и лечение. - М.: ЗАО «Изд. БИНОМ», 2004. - 240 с.Ивлева А.Я., Старостина Е.Г. Ожирение - проблема медицинская. - М.: 2002. - 176 с.Ивлева А.Я., Старостина Е.Г. Ожирение - проблема медицинская. - М.: 2002. - 176 с.Свиридова С.Т. Лишний вес: в новый год налегке // Фармацевтический вестник, 2009; 38: P. 16-17.Свиридова С.Т. Лишний вес: в новый год налегке // Фармацевтический вестник, 2009; 38: P. 16-17.American Obesity Association. AOA fact Sheets: Obesity in the USA // www. Obesity.org. 2007.American Obesity Association. AOA fact Sheets: Obesity in the USA // www. Obesity.org. 2007.Bray G.A., Blakburn G.L., Ferguson J.M. et al. Sibutramine produces dose-related weight loss // Obesity Res., 1999; 7: P. 189-198.Bray G.A., Blakburn G.L., Ferguson J.M. et al. Sibutramine produces dose-related weight loss // Obesity Res., 1999; 7: P. 189-198.Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment оf obesity and associated conditions // Arq. Bras. Endocrinol. Metabol., 2009; 3: P. 262-270.Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment оf obesity and associated conditions // Arq. Bras. Endocrinol. Metabol., 2009; 3: P. 262-270.Davidson M.H., Hauptman J., DiGirolamo K. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial // JAMA, 1999; 2: P. 235-242.Davidson M.H., Hauptman J., DiGirolamo K. et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial // JAMA, 1999; 2: P. 235-242.De Koning L., Merchant A.T., Pogue J., Anand S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies // Eur. Heart J., 2007; 2: P. 850-856.De Koning L., Merchant A.T., Pogue J., Anand S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies // Eur. Heart J., 2007; 2: P. 850-856.Hellmich N. Obesity linked to specific cancers // USA TODAY, 2009;- 11. - 05.Hellmich N. Obesity linked to specific cancers // USA TODAY, 2009;- 11. - 05.Hubert H.B., Feinleib M., McNamara P.H. Obesity as an independent risk factor for cardiovascular disease: a 26-yeae follow-up of participants in the Framingham Heart Study // Circulation, 1993; 10: P. 968-977.Hubert H.B., Feinleib M., McNamara P.H. Obesity as an independent risk factor for cardiovascular disease: a 26-yeae follow-up of participants in the Framingham Heart Study // Circulation, 1993; 10: P. 968-977.Lavie C.J., Milani R.V., Artham S.M. et al. The obesity paradox, weight loss, and coronary disease // Am. J. Med., 2009;12: P. 1106-1114.Lavie C.J., Milani R.V., Artham S.M. et al. The obesity paradox, weight loss, and coronary disease // Am. J. Med., 2009;12: P. 1106-1114.Moklad A.H., Bowman B.A., Ford E.S. et al. The continuing epidemics of obesity and diabetes in the United States // JAMA, 2001; 11: P. 1195-1200.Moklad A.H., Bowman B.A., Ford E.S. et al. The continuing epidemics of obesity and diabetes in the United States // JAMA, 2001; 11: P. 1195-1200.Obesity impact on GER symptoms examined // www. Medwire-news.md. 2009.Obesity impact on GER symptoms examined // www. Medwire-news.md. 2009.Sjostrom L., Rissanen A., Andersen T. et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients // Lancet,2008; 5: P. 167-172.Sjostrom L., Rissanen A., Andersen T. et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients // Lancet,2008; 5: P. 167-172.Uretsky S., Masserli F.H., Baugalore S. et al. Obesity paradox in patients with hypertention and coronary artery disease // Am. J. Med., 2007; 7: P. 863-870.Uretsky S., Masserli F.H., Baugalore S. et al. Obesity paradox in patients with hypertention and coronary artery disease // Am. J. Med., 2007; 7: P. 863-870.

The authors declare that there are no conflicts of interest present.